Skip to main content

Jaguar Health Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

JAGX$0.44+7.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

September 30, · December 31,
(In thousands, except share and per share data) · 2024 · 2023
(unaudited)
Assets
Current assets:
Cash$13,269$6,469
Accounts receivable, net1,2491,967
Other receivable57217
Inventory9,6749,189
Prepaid expenses and other current assets12,39410,121
Total current assets36,64327,963
Property and equipment, net476496
Operating lease - right-of-use asset1,0571,176
Intangible assets, net18,94720,116
Other assets1,3431,012
Total assets$58,466$50,763
Liabilities, Redeemable preferred stock, and Stockholders' equity
Current liabilities:
Accounts payable$4,552$4,974
Accrued liabilities3,2973,798
Deferred revenue170—
Operating lease liability, current368348
Notes payable, net of discount (includes note designated at Fair Value Option amounting to $11.1 million as of September 30, 2024, and $0 December 31, 2023, respectively)11,4874,867
Total current liabilities19,87413,987
Operating lease liability, net of current portion754886
Deferred revenue - long term595—
Notes payable, net of discount, net of current portion (includes notes designated at Fair Value Option amounting to $21.7 million as of September 30, 2024, and $31.0 million December 31, 2023, respectively)21,66030,993
Total liabilities42,88345,866
Commitments and contingencies (See Note 6)
Redeemable preferred stock: $0.0001 par value; 179 and 0 shares designated from 10,000,000 preferred stock authorized at September 30, 2024, and December 31, 2023; 99 and 0 shares issued and outstanding at September 30, 2024 and December 31, 20232,485—
Stockholders' equity
Series G convertible preferred stock: $0.0001 par value; 137 and 137 shares designated from 10,000,000 preferred stock authorized at September 30, 2024, and December 31, 2023; 0 and 122 shares issued and outstanding at September 30, 2024 and December 31, 2023——
Series H convertible preferred stock: $0.0001 par value; 105 and 105 shares designated from 10,000,000 preferred stock authorized at September 30, 2024, and December 31, 2023; zero shares issued and outstanding at September 30, 2024 and December 31, 2023——
Series I convertible preferred stock: $0.0001 par value; 118 and 118 shares designated from 10,000,000 preferred stock authorized at September 30, 2024, and December 31, 2023; 0 and 56 shares issued and outstanding at September 30, 2024 and December 31, 2023——
Common stock - voting: $0.0001 par value, 298,000,000 shares authorized at September 30, 2024, and December 31, 2023; 10,420,964 and 1,223,553 issued and outstanding at September 30, 2024, and December 31, 20231—
Common stock - non-voting: $0.0001 par value, 50,000,000 shares authorized at September 30, 2024, and December 31, 2023; 9 shares issued and outstanding at September 30, 2024, and December 31, 2023——
Additional paid-in capital350,859313,861
Noncontrolling interest(514)(64)
Accumulated deficit(336,561)(308,248)
Accumulated other comprehensive loss(687)(652)
Total stockholders' equity13,0984,897
Total liabilities, redeemable preferred stock and stockholders' equity$58,466$50,763
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.